17,261 trials
Coronary Heart Disease
Primary: Change From Baseline in % Flow Mediated Dilatation (FMD) — 0.09; 0.32 %FMD
Chronic Idiopathic Constipation
Primary: Number of Participants With Adverse Events — 3; 6; 2; 6 Participants
Metastatic Melanoma · Mucosal Melanoma · Stage IV Cutaneous Melanoma AJCC v6 and v7
Primary: Progression-free Survival (PFS) — 139; 94 days
Parkinson Disease · Anxiety
Primary: The Number of Participants Who Fail to Complete the 12-week Study on Study Drug. — 7; 0 Participants
Meningitis, Meningococcal
Primary: Human Serum Bactericidal Activity (hSBA) Adjusted Geometric Mean Titers (GMTs) Against All of N. Meningitidis Serogroup B Test Strains (Pooled), One Month After Last…
Recurrent Melanoma · Stage IIIA Melanoma · Stage IIIB Melanoma
Primary: Best Overall Response Rate (BORR) — 2; 17; 1 Participants
Chronic Kidney Disease · Hyperphosphatemia
Primary: Percentage of Participants Achieving Age-Specific Kidney Disease Outcomes Quality Initiative (KDOQI) Targets for Serum Phosphate Level Following 8 Weeks of Lanthanum…
Dyslipidemia
Primary: Absolute Change From Baseline in HDL-C Level\n — 17.18; 31.42; 36.45; 2.31 mg/dL
Multiple Myeloma
Primary: Median Progression-Free Survival (PFS) — 8.5 Months
Acute Myeloid Leukemia Post Cytotoxic Therapy · Recurrent Childhood Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia
Primary: Number of Participants With a Dose-limiting Toxicity — 1 Participants
Chronic Hepatitis D Infection With Hepatitis B
Primary: HDV RNA Response at Week 24 — 15; 16; 23; 1 Participants — p=<.0001
Cystic Fibrosis
Primary: Change in Percent Predicted FEV1 — 1.633; 0.800; 0.890 change from baseline in ppFEV1
HIV-1 Infection
Primary: Number of Participants Who Met the Study-defined Composite Safety Endpoint — 3 Participants
Lymphoma, Follicular
Primary: Percentage of Participants Achieving Complete Response (CR) at End of Induction (EOI), as Determined by the Independent Review Committee (IRC) Using Modified Lugano 2014…
Infection · Bacteremia
Primary: Patient Clinical Response to Telavancin — 32 Participants